Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F14%3A10218399" target="_blank" >RIV/00216208:11110/14:10218399 - isvavai.cz</a>

Alternative codes found

RIV/00064165:_____/14:10218399

Result on the web

<a href="http://dx.doi.org/10.1007/s00415-013-7196-4" target="_blank" >http://dx.doi.org/10.1007/s00415-013-7196-4</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s00415-013-7196-4" target="_blank" >10.1007/s00415-013-7196-4</a>

Result language

angličtina

Original language name

Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis

Original language description

Patients with highly active relapsing-remitting multiple sclerosis (RRMS) are at greater risk for disease progression and may respond differently to MS therapeutics than those with less active disease. The current post hoc analysis evaluated the effectsof daclizumab high-yield process (DAC HYP) vs. placebo in patients with highly active RRMS in the SELECT study. Highly active RRMS was defined as patients with a parts per thousand yen2 relapses in the year before randomization and a parts per thousand yen1 gadolinium-enhancing (Gd+) lesion at baseline. Because results were similar in the DAC HYP dose groups, data from the DAC HYP arms were pooled for analysis. Treatment with DAC HYP resulted in similar effects in highly active (n = 88) and less active(n = 506) RRMS patients. DAC HYP reduced the annualized relapse rate by 50 % and 51 % in the highly active (p = 0.0394) and less active (p < 0.0001) groups vs. placebo, respectively (interaction p = 0.82). DAC HYP reduced new/newly-enlarg

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FH - Neurology, neuro-surgery, nuero-sciences

OECD FORD branch

—

Project

—

Continuities

Z - Vyzkumny zamer (s odkazem do CEZ)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2014

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Journal of Neurology

ISSN

0340-5354

e-ISSN

—

Volume of the periodical

261

Issue of the periodical within the volume

2

Country of publishing house

DE - GERMANY

Number of pages

8

Pages from-to

316-323

UT code for WoS article

000330963200009

EID of the result in the Scopus database

—